• Gert O De Meerleer, Valérie H Fonteyne, Luc Vakaet, Geert M Villeirs, Ludwig Denoyette, Antony Verbaeys, Nicolas Lummen, and Wilfried J De Neve.
• Department of Radiation Therapy, Ghent University Hospital, Gent, Belgium. gert@krtkg1.ugent.be
• Radiother Oncol. 2007 Feb 1; 82 (2): 160-6.

PurposeTo report on late morbidity and biochemical relapse-free survival (bRFS) after intensity-modulated radiation therapy (IMRT) for prostate cancer.MethodsBetween 1998 and 2005 133 patients were treated with IMRT for T(1-4) N0 M0 prostate cancer. The median follow-up time was 36 months. In a first cohort, patients received a median planning target volume (PTV) dose of 74 Gy with a hard constraint on maximum rectum dose of 72 Gy (74R72, n=51). Later, median PTV and maximum rectum dose were increased to 76 and 74 Gy, respectively (76R74; n=82). We defined low-risk (n=20), intermediate-risk (n=70) and high-risk (n=43) groups. Androgen deprivation was given to patients in the intermediate- and high-risk group. Late gastro-intestinal (GI) and genito-urinary (GU) morbidity and biochemical relapse, in accordance with the ASTRO consensus, were recorded.ResultsWe observed grade 2 GI (17%) and GU (19%), grade 3 GI (1%) and GU (3%) late toxicities. Except for hematuria, the median duration of side-effects was 6 months. Biochemical relapse-free survival (bRFS) at 3 and 5 years was 88% and 83%, respectively, with a significantly better 3-year bRSF for the 76R74 than for the 74R72 group (p=0.01). Five-year bRFS for patients in the low-risk, intermediate-risk and high-risk group was 100%, 94% and 74%, respectively (p<0.01).ConclusionIMRT for localized or locally advanced prostate cancer combines low morbidity with excellent biochemical control.

22 keywords...

hide…